Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a ...

Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset——Joint poster with Bachem demonstrates ...

As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...

Researchers from VIB and VUB now provide an interactive tool, based on a single-cell RNA-sequencing (scRNA-seq) atlas of the ...

Gene mutations have consequences both good and bad—from resistance to conditions like diabetes to susceptibility to certain ...

Zymo’s Quick DNA/RNA Viral MagBead Kit was automated using Analytik Jena’s Cybio FeliX pipetting robot. The CyBio FeliX ...

Shares of Avidity Biosciences RNA rose more than 12% on Wednesday after the company announced that it is expanding its ...

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...

Efforts, both nationally and local, have been made to improve the treatment of sepsis. Last year Gov. Dan McKee signed a law ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on RNA stock, giving a Buy rating yesterday. Joseph Schwartz has given his Buy rating due to a combination of factors that ...

University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...